These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15591104)

  • 61. Carperitide induces coronary vasodilation and limits infarct size in canine ischemic hearts: role of NO.
    Asanuma H; Sanada S; Asakura M; Asano Y; Kim J; Shinozaki Y; Mori H; Minamino T; Takashima S; Kitakaze M
    Hypertens Res; 2014 Aug; 37(8):716-23. PubMed ID: 24694647
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
    Eckly AE; Lugnier C
    Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.
    Zhang HT; Huang Y; Mishler K; Roerig SC; O'Donnell JM
    Psychopharmacology (Berl); 2005 Oct; 182(1):104-15. PubMed ID: 16010541
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phosphodiesterase type 4 inhibitor prevents acute lung injury induced by cardiopulmonary bypass in a rat model.
    Hamamoto M; Suga M; Nakatani T; Takahashi Y; Sato Y; Inamori S; Yagihara T; Kitamura S
    Eur J Cardiothorac Surg; 2004 May; 25(5):833-8. PubMed ID: 15082290
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Post-ischemic cardioprotection by A2A adenosine receptors: dependent of phosphatidylinositol 3-kinase pathway.
    Boucher M; Pesant S; Falcao S; de Montigny C; Schampaert E; Cardinal R; Rousseau G
    J Cardiovasc Pharmacol; 2004 Mar; 43(3):416-22. PubMed ID: 15076226
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
    Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Beneficial effects of adenosine A(2a) agonist CGS-21680 in infarcted and stunned porcine myocardium.
    Lasley RD; Jahania MS; Mentzer RM
    Am J Physiol Heart Circ Physiol; 2001 Apr; 280(4):H1660-6. PubMed ID: 11247777
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Amelioration of ischemia/reperfusion-induced myocardial infarction by the 2-alkynyladenosine derivative 2-octynyladenosine (YT-146).
    Sasamori J; Aihara K; Yoneyama F; Sato I; Kogi K; Takeo S
    J Cardiovasc Pharmacol; 2006 Apr; 47(4):614-20. PubMed ID: 16680077
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor.
    Ge ZD; Peart JN; Kreckler LM; Wan TC; Jacobson MA; Gross GJ; Auchampach JA
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1200-10. PubMed ID: 16985166
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats.
    Kiss K; Csonka C; Pálóczi J; Pipis J; Görbe A; Kocsis GF; Murlasits Z; Sárközy M; Szűcs G; Holmes CP; Pan Y; Bhandari A; Csont T; Shamloo M; Woodburn KW; Ferdinandy P; Bencsik P
    Pharmacol Res; 2016 Nov; 113(Pt A):62-70. PubMed ID: 27521836
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Adenosine A2-receptor activation at reperfusion reduces infarct size and improves myocardial wall function in dog heart.
    Schlack W; Schäfer M; Uebing A; Schäfer S; Borchard U; Thämer V
    J Cardiovasc Pharmacol; 1993 Jul; 22(1):89-96. PubMed ID: 7690102
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The effects of the endothelin ETA receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion.
    McMurdo L; Thiemermann C; Vane JR
    Br J Pharmacol; 1994 May; 112(1):75-80. PubMed ID: 8032665
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of selective inhibition of cytochrome P-450 omega-hydroxylases and ischemic preconditioning in myocardial protection.
    Nithipatikom K; Endsley MP; Moore JM; Isbell MA; Falck JR; Campbell WB; Gross GJ
    Am J Physiol Heart Circ Physiol; 2006 Feb; 290(2):H500-5. PubMed ID: 16214838
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Adenosine A(2A) receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model.
    McPherson JA; Barringhaus KG; Bishop GG; Sanders JM; Rieger JM; Hesselbacher SE; Gimple LW; Powers ER; Macdonald T; Sullivan G; Linden J; Sarembock IJ
    Arterioscler Thromb Vasc Biol; 2001 May; 21(5):791-6. PubMed ID: 11348876
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.
    Sawanishi H; Suzuki H; Yamamoto S; Waki Y; Kasugai S; Ohya K; Suzuki N; Miyamoto K; Takagi K
    J Med Chem; 1997 Sep; 40(20):3248-53. PubMed ID: 9379444
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Diabetes abolishes sildenafil-induced cGMP-dependent protein kinase-I expression and cardioprotection.
    Jamnicki-Abegg M; Weihrauch D; Chiari PC; Krolikowski JG; Pagel PS; Warltier DC; Kersten JR
    J Cardiovasc Pharmacol; 2007 Dec; 50(6):670-6. PubMed ID: 18091584
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Phosphodiesterase type 4 inhibition of activated polymorphonuclear leukocytes in a simulated extracorporeal circulation model.
    Sato Y; Hiramatsu Y; Homma S; Sato S; Onizuka M; Sakakibara Y
    J Thorac Cardiovasc Surg; 2003 Jan; 125(1):172-7. PubMed ID: 12539001
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Early adenosine receptor activation ameliorates spinal cord reperfusion injury.
    Reece TB; Tribble CG; Okonkwo DO; Davis JD; Maxey TS; Gazoni LM; Linden J; Kron IL; Kern JA
    J Cardiovasc Med (Hagerstown); 2008 Apr; 9(4):363-7. PubMed ID: 18334890
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats.
    Takahama H; Minamino T; Asanuma H; Fujita M; Asai T; Wakeno M; Sasaki H; Kikuchi H; Hashimoto K; Oku N; Asakura M; Kim J; Takashima S; Komamura K; Sugimachi M; Mochizuki N; Kitakaze M
    J Am Coll Cardiol; 2009 Feb; 53(8):709-17. PubMed ID: 19232905
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Bimakalim, an ATP-sensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs.
    Mizumura T; Nithipatikom K; Gross GJ
    Circulation; 1995 Sep; 92(5):1236-45. PubMed ID: 7648671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.